Pale Fire Capital SE’s Akebia Therapeutics AKBA Stock Holding History

Pale Fire Capital SE’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,210	Closed	-$137K	–	62
2025 Q3	$137K	Buy	+50,210	New	+$167K	0.02%	49

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pale Fire Capital SE's AKBA Position: Q4 2025 in Review

Pale Fire Capital SE sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 50,210 shares — an estimated $137K sold.

Pale Fire Capital SE first reported a position in AKBA in Q3 2025 and held it in 1 quarter. The position peaked at $137K in Q3 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

Pale Fire Capital SE reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
Pale Fire Capital SE sold 50,210 Akebia Therapeutics shares in Q4 2025, an estimated $137K.
Pale Fire Capital SE first reported a position in Akebia Therapeutics in Q3 2025 and held it in 1 quarter.
Pale Fire Capital SE's Akebia Therapeutics position peaked at $137K in Q3 2025.
165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on Pale Fire Capital SE's 13F filing for Q4 2025, filed 13 Feb 2026.